Engineered Platelet-Based Micro/Nanomotors for Cancer Therapy

Small. 2021 Dec;17(52):e2104912. doi: 10.1002/smll.202104912. Epub 2021 Nov 5.

Abstract

Engineered platelets (PLT) can bring new possibilities for diseases treatment due to the specific response for a variety of physiological disease environments. However, the deep penetration of engineered PLT in diseased tissues such as tumor is still an important challenge that restricts the therapeutic effect. Herein, the engineered PLT micromotor (PLT@PDA-DOX) is constructed by a universal self-polymerization modification method of dopamine, and the chemotherapeutic drug doxorubicin (DOX) is loaded by both π-π stacking interaction with polydopamine (PDA) and cellular endocytosis of PLT. The experimental results prove that PLT@PDA-DOX can target to tumor site by the specific binding of PLT with cancer cells, and then the secondary PLT-derived microparticles (PMP@PDA-DOX) are released with the activation of PLT@PDA-DOX by tumor microenvironment (TME). Besides, benefiting from the photothermal conversion capability of PDA, PLT@PDA-DOX micromotors and PMP@PDA-DOX nanomotors are driven by near-infrared light to realize deep penetration. And the PLT-based micro/nanomotors with propulsion capability possess good performance for tumor ablating in vitro and in vivo. In consideration of the operability, mildness, universality of this modification method and the good biocompatibility of PDA, this work may provide a general paradigm for the construction of engineered cells in disease treatment.

Keywords: cancer therapy; drug delivery; micromotors; microparticles; platelet-derived platelets.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Platelets
  • Cell Line, Tumor
  • Doxorubicin / therapeutic use
  • Drug Carriers
  • Humans
  • Nanoparticles*
  • Neoplasms* / drug therapy
  • Phototherapy
  • Tumor Microenvironment

Substances

  • Drug Carriers
  • Doxorubicin